Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway

British Journal of Cancer

Volumn 106, Issue 9, 2012, Pages 1571-1578

  Burger, E A ^a   Ortendahl, J D ^b   Sy, S ^b   Kristiansen, I S ^a   Kim, J J ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

cervical cancer screening; Cost effectiveness; HPV vaccination

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGE; ARTICLE; CANCER PREVENTION; CANCER SCREENING; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; FEMALE; GOVERNMENT; HUMAN; NORWAY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

ADULT; COST-BENEFIT ANALYSIS; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MODELS, THEORETICAL; NORWAY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PROGNOSIS; QUALITY-ADJUSTED LIFE YEARS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84862818899     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.94     Document Type: Article

References (41)

1. Aas E (2009) Pecuniary compensation increases participation in screening for colorectal cancer. Health Econ 18(3): 337-354
2. Arbyn M, Sasieni P, Meijer CJLM, Clavel C, Koliopoulos G, Dillner J (2006) Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24: 78-89
3. Bidus MA, Maxwell GL, Kulasingam S, Rose GS, Elkas JC, Chernofsky M, Myers ER (2006) Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening. Obstet Gynecol 107(5): 997-1005
4. Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, Moller H, Hakama M, Parkin DM (2005) Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 14(3): 677-686 (Pubitemid 40489214)
5. Cancer Registry of Norway (2009) Annual Report 2008. Oslo. Available at: http://www.kreftregisteret.no/Global/Publikasjoner%20og%20rapporter/ Special%20Issue/Special-Issue-Cancer-in-Norway-2009.pdf (accessed 6 January 2011)
6. Cancer Registry of Norway (2011) Cancer in Norway 2009. Special Issue: Cancer Screening in Norway. Oslo. Available at: http://www.kreftregisteret. no/Global/Publikasjoner%20og%20rapporter/Special%20Issue/Special-Issue-Cancer- in-Norway-2009.pdf (accessed 6 January 2011)
7. Cuzick J, Clavel C, Petry KU, Meijer CJLM, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T (2006a) Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119(5): 1095-1101 (Pubitemid 44116919)
8. Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J (2006b) New dimensions in cervical cancer screening. Vaccine 24: 90-97
9. Dasbach EJ, Largeron N, Elbasha EH (2008) Assessment of the costeffectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model. Expert Rev Pharmacoecon Outcomes Res 8(5): 491-500
10. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T (2008) Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337(7676): doi. 10.1136/bmj.a1754
11. Federal Reserve (2011) Historical Rates for the Norwegian Krone. Available at: http://www.federalreserve.gov/RELEASES/H10/Hist/dat00-no.htm (accessed 13 June 2011)
12. Franco EL (2003) Chapter 13: Primary screening of cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monogr 2003(31): 89-96
13. Goldhaber-Fiebert JD, Stout NK, Ortendahl J, Kuntz KM, Goldie SJ, Salomon JA (2007) Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr 5: 11
14. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ (2008) Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 100(5): 308-320 (Pubitemid 351480523)
15. Goldie SJ (2003) Chapter 15: Public health policy and cost-effectiveness analysis. J Natl Cancer Inst Monogr 2003(31): 102-110
16. Goldie SJ, Kim JJ, Myers E (2006) Cost-effectiveness of cervical cancer screening. Vaccine 24: 164-170
17. Goldie SJ, Kim JJ, Wright TC (2004) Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 103(4): 619-631 (Pubitemid 40459019)
18. Hakama M, Hristova L (1997) Effect of screening in the Nordic cancer control up to the year 2017. Acta Oncol 36(2): 119-128 (Pubitemid 27168748)
19. Kim JJ, Goldie SJ (2008) Health and economic implications of HPV vaccination in the United States. N Engl J Med 359(8): 821-832
20. Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, Goldie SJ (2007) Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 166(2): 137-150 (Pubitemid 47227293)
21. Kim JJ, Wright TC, Goldie SJ (2005) Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst 97(12): 888-895 (Pubitemid 41417940)
22. Kulasingam SL, Myers ER, Lawson HW, McConnell KJ, Kerlikowske K, Melnikow J, Washington AE, Sawaya GF (2006) Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests. Obstet Gynecol 107(2): 321-328
23. Molden T, Kraus I, Karlsen F, Skomedal H, Hagmar B (2006) Human papillomavirus E6/E7 rnRNA expression in women younger than 30 years of age. Gynecol Oncol 100(1): 95-100 (Pubitemid 41815056)
24. Molden T, Kraus I, Karlsen F, Skomedal H, Nygard JF, Hagmar B (2005) Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4136 women o30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 14(2): 367-372 (Pubitemid 40270098)
25. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348(6): 518-527 (Pubitemid 36159887)
26. Norwegian Directorate of Health (2007) Health Effects of Socio-Economic Analyses. Available at: http://www.helsedirektoratet.no/vp/multimedia/archive/ 00020/IS-1435-20969a.pdf (accessed on 6 January 2011)
27. Norwegian Directorate of Health (2010) Activity-based funding 2010/2011. Available at: http://www.helsedirektoratet.no/finansieringsordninger/regelverk- innsatsstyrt-finansiering-isf-2011-78057 (accessed 10 December 2010)
28. Norwegian Finance Department (2005) Guideline for Economic Analysis. Available at: http://www.regjeringen.no/upload/kilde/fin/reg/2005/0029/ddd/pdfv/ 266324-veileder-i-samfunnsok-analyse-trykket.pdf (accessed 6 January 2011)
29. Norwegian Medical Association (2010a) Guidelines for Cervical Cancer. Available at: http://www.legeforeningen.no/id/153817.0 (accessed 11 November 2010)
30. Norwegian Medical Association (2010b) Normal tariff for private general practice 2010-2011. Available at: www.legeforeningen.no/normaltariff/ Fastlegetariff-2010.pdf (accessed 1 November 2010)
31. Norwegian Medical Association (2010c) Normal tariff for private specialist practice 2010-2011. Available at: www.legeforeningen.no/normaltariff/ Normaltariff-2010.pdf (accessed 10 November 2010)
32. Norwegian Medicines Agency (2010) Reimbursement report: HPV-Vaccine Gardisil for prevention of HPV infection, cervical cancer and genital warts. Available at: http://www.legemiddelverket.no/upload/144901/09-16212- 8%20RAPPORT%201622714-underskrevet.pdf (accessed 1 May 2011)
33. Nygard JF, Nygard M, Skare GB, Thoresen SO (2006) Pap smear screening in women under 30 in the Norwegian Coordinated Cervical Cancer Screening Program, with a comparison of immediate biopsy vs Pap smear triage of moderate dysplasia. Acta Cytologica 50(3): 295-302 (Pubitemid 43841438)
34. Peto J, Gilham C, Fletcher O, Matthews FE (2004) The cervical cancer epidemic that screening has prevented in the UK. Lancet 364(9430): 249-256 (Pubitemid 38942814)
35. Sherlaw-Johnson C, Philips Z (2004) An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. Br J Cancer 91(1): 84-91 (Pubitemid 39013049)
36. Sherman ME (2003) Chapter 11: Future Directions in Cervical Pathology. J Natl Cancer Inst Monogr 2003(31): 72-79
37. Solomon D (2003) Chapter 14: Role of Triage Testing in Cervical Cancer Screening. J Natl Cancer Inst Monogr 2003(31): 97-101
38. Statistics Norway (2011) Available at: http://www.ssb.no/english/ (accessed 10 January 2011)
39. Stinnett AA, Paltiel AD (1997) Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means. Med Decis Making 17(4): 483-489 (Pubitemid 27444320)
40. World Health Organization (2003) World Health Survey. Available at: http://www.ssb.no/whs-en/(accessed 5 January 2011)
41. Wright TC, Massad S, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D (2007) 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 197(4): 346-355 (Pubitemid 47464164)